Abstract
SUMMARY Our understanding of multiple myeloma biology over the last two decades has led to a marked improvement in progression-free and overall survival for the majority of patients. The introduction of novel agents, improvement in administration of high-dose therapy with autologous stem cell support, along with supportive care measures have enabled the myeloma researchers to once again debate the curability of this disease. The present article is a succinct review of the progress that has been made and the impediments to curability of this disease.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
